Myopia and Genetic Testing: What Can It Tell Your Family?

Before ordering a test, name the question

“Myopia runs in our family. Would a genetic test tell us what to do?” That question can mean several different things. A parent may want to know whether a child will become nearsighted, why a very young child has a strong prescription, or which treatment is most likely to work. These are separate questions. A test that helps with one does not automatically answer the others.

Start by asking what the eye-care professional is trying to find out. Is the concern about common childhood myopia, a possible inherited eye condition, or a broader medical finding? The examination, age at onset and family history help frame that discussion. A commercially available report should not be allowed to define the question simply because it is easy to order.

The International Myopia Institute's 2025 genetics report describes major research progress while distinguishing promising risk scores from routine clinical use. It also describes a different role for testing when rare genetic changes may explain severe or syndromic myopia. This distinction is the foundation of a useful conversation. ^[1]

Common myopia does not follow one simple gene

For many families, myopia reflects the combined influence of many genetic variants and the environment. Having a nearsighted parent is useful information, but it is not a timetable for the child's prescription. Nor does a family history of good distance vision rule out myopia. MedlinePlus explains that inheritance is complex and that environmental factors also contribute. ^[2]

Think of family history as part of the record, rather than as a yes-or-no verdict. Write down which relatives needed glasses, roughly when they started, and whether anyone had a diagnosed inherited eye condition. Distinguish a confirmed diagnosis from a family description such as “very bad eyes.” If you do not know the details, say so. A gap in the history is more useful than a guessed medical label.

Avoid asking a child to interpret the family tree as a prediction of their future. The point is to give the clinician information that may guide assessment and follow-up. The family-history guide explains the everyday risk discussion. This page focuses on what genetic testing might add, where it may not help and what families should ask before proceeding.

What is a polygenic risk score?

A polygenic risk score combines information from many genetic variants into a research estimate. The word “polygenic” means many genes are involved. Such a score may help researchers study which groups are more likely to develop a particular outcome. It is not the same as finding a single genetic change that explains an inherited condition.

The 2025 IMI report describes potential for risk prediction when genetic and environmental information are considered together, but says these scores are not yet ready for clinical application. A promising research tool should therefore not be presented as a routine way to select a child's atropine concentration, contact lens or glasses design. ^[1]

If someone offers a score, ask what population it was developed in, what outcome it predicts and whether it has been checked in people like your child. Ask what would actually change in care if the result were higher or lower. “It gives more information” is not enough by itself. Useful information should have an understandable purpose, known limits and a plan for discussing the result.

When the investigation has a different purpose

Very early or high myopia can require a broader assessment than the usual school-age risk discussion. The IMI report on high myopia in infants and young children emphasizes looking for associated eye or systemic conditions and considering specialist investigation when indicated. That does not mean every child with a strong prescription has a rare disorder. It means the pattern and examination deserve careful attention. ^[3]

A specialist may want details about birth history, development, other medical diagnoses, earlier eye findings and relatives with a known condition. Some children may be referred to professionals with experience in inherited eye disease or clinical genetics. The exact pathway depends on the findings. A parent should not have to work out the appropriate test panel from an online symptom list.

Ask the clinician to explain the reason for any referral in plain language. Is the aim to clarify a diagnosis, plan monitoring, investigate a wider health concern or advise relatives? Write down what happens while the investigation is arranged. Necessary vision correction and support for the child's development should not be lost while everyone waits for a genetic result.

A result can be positive, negative or uncertain

Before testing, ask how the possible results will be explained. A finding may support a particular diagnosis, fail to find an explanation, or leave uncertainty about whether a genetic change matters. The family needs a plan for each possibility. An uncertain finding should not be translated at home into a definite diagnosis or a treatment instruction.

A negative result also needs context. Ask which conditions or types of genetic change the test could assess, and which it could not. The absence of a reported finding is not a reason to disregard a clinical problem that still needs care. Likewise, a risk-related result does not tell you exactly how a child's eyes will change in the next year.

Also ask whether the laboratory or clinic has a process for reviewing an uncertain finding later. Find out who keeps contact details current and whether a new interpretation would be communicated. Do not assume that every service automatically checks old results whenever research changes.

One useful question is, “What remains true about our care plan whatever the result says?” That can help separate immediate needs from questions that testing might clarify. The clinician should explain any changes to examinations, referrals or family advice. If an answer is unclear, request a written explanation or a follow-up conversation rather than trying to resolve it through a consumer report alone.

Ask about consent, privacy and the family

Genetic information can have implications beyond the person providing the sample. Before agreeing, ask who will receive the results, where the sample and data will be stored and whether they may be used for other purposes. The answers should come from the actual testing service and clinical team. Privacy policies and legal protections differ between services and locations; this article does not assume they are all equivalent.

Ask whether the test is clinical care, research or a consumer service. Find out who is responsible for interpreting the report and whether genetic counseling is available. Request a clear explanation of the total cost, including any follow-up discussion, and whether testing relatives might later be considered. A low advertised price may not describe the full process.

For a child, the conversation should also respect their age and understanding. Explain why a sample is being considered without describing their genes as a fault. Make space for questions about the procedure and the information it might produce. A careful consent discussion is part of the service, not an inconvenience that should be rushed past.

Personalized care already uses more than a DNA report

The absence of a routine genetic treatment selector does not mean myopia care is one-size-fits-all. The examination, measured change, vision, eye health, treatment suitability and the family's ability to carry out a routine already matter. The IMI clinical management guidance describes assessment and ongoing management that take the child's risk factors and circumstances into account. ^[4]

A family can contribute useful detail without buying a test. Bring earlier prescriptions, dated measurements if available and an honest account of the treatment routine. Explain concerns about handling lenses, comfort, school needs or access to follow-up. Those details may change how a plan is supported even when they do not change the underlying diagnosis.

Ask the clinician to connect each recommendation to the question it addresses. Glasses that improve distance vision, monitoring that tracks change and a specialist investigation that seeks a diagnosis have different roles. A good explanation should let you describe those roles back. No genetic result should become a reason to change a medicine, abandon prescribed correction or skip an examination without professional advice.

Leave with a decision you can explain

At the end of the discussion, try a short summary: “We are considering this test to answer this question. These are the possible limits. This is who will explain the result. This is what we do in the meantime.” If part of that summary is missing, ask for clarification before making a purchase or sending a sample.

The American Academy of Orthokeratology and Myopia Control (AAOMC) offers patient information about myopia and management options. It can help families prepare a wider treatment discussion, but its inclusion here is not an endorsement of a genetic testing service. ^[5] The younger-child guide explains why an early diagnosis may need its own assessment pathway.

Research is moving forward, and recommendations may change as tools are validated. For now, a careful question is more useful than a broad promise of “personalized vision.” The best next step is the one that has a clear purpose for your child, appropriate professional interpretation and a practical plan for the information it may provide.